Well, I made some nice money here (on the long side). Not that it really matters.
But hoping somebody chokes and dies because you can not invest well? You are sick. Get help.
So, you think the way to win is via illegal stock manipulation?
I assume from that you do not see MNKD as a viable company?
It would do exactly the oppoiste to shorts as it does to a long.
For a long, it gives them a few extra pennies, but weakens the stock as it spends needed cash. Overall not really a good thing as they might then need to turn around and raise cash.
For shorts, they would have to pay the dividend. But more might be interested in shorting the stock as the impair future prospects.
Get out of all this "short", "manipulation", "MMs", "hedge funds" nonsense.
SPPI is where it is for a very simple clear reason. They are basically a specialty pharma that has seval low value drugs. It is not a dev stage biotech. As such, it has to show that it can make a real profit, and that it has failed to do.
P.S.: I do agree that the pipeline has some potential value beyond this. But given their reord to date, and some iffy questions, it is not going to valued in by the market.
If you mean the trial data, it should be ready any day now.
Enrollment closed mid July, they are gathering 3 months of data. So even allowing a little slop it has been a month since they could have started putting it together. And it takes no time at all to analyse top line numbers.
A) They have not yet released OS numbers, so you have no idea what that is.
B) The comparator (Darcabazine) is particularly nasty.
C) Learn the difference be median and mean. It matters.
The 2 MCK inhibitors, binimetinib (today's news) and selumetinib are both in dozens of trials. Many P2s and a few P3s.
Both these drugs had an odd history, ARRY partnered them, but because of mergers the partners had to return them with cash. They recently re-partnered both in EU (modest cash, decent royalties).
LGX818 (a BRAF inhibitor) they obtained recently obtained from Norvartis. It was being studied in conjunction with binimetinib, and other trials. In at least one P3.
Filanisib was their wholly owned Myeloma drug that they were pushing hard, but when the 2 MCKs were returned they have switched focus to those. It is about P3 ready.
Several other candidates floating around in earlier stages, some partnered,
. As stanly said, they are likely to have selumetinib and 818 on the market by then.
. They will possibly have filanisib and 797 in pivitol trials then.
. They have a significant number of candidates (clinical and preclinical) licensed out to BP
. That Loxo deal might be interesting
. Who knows, mayby that dog we licensed to ONTY could bring in some cash.
I would assume there is no milestone for the P3 success. First, trial success can be a slippery metric. Second, they have not announed it.
A reasonable expectency would be EMA approval as the next milestone. Something close to $100M? H1 '17 I would hope.
This was an XML cleanup only. The entry prior to the change had a maximum age field that was blank, the change removed the field.
Look at the previous text version (click on updated before xxx) and you will see at the bootom of the Recruitment Information section:
minimu age: 18 years
healthy volunteers: no
And the exact same information after the change. No maximum age was previous there.
And as somebody else posted, the requirment is for recruitment. Does no effect those in the trial.